PubMed: 33965067 Phase 2a: Weight Loss Efficacy Study (NCT03224429) Study Title: "Efficacy and Safety of Cagrilintide for Weight Management in Adults With Overweight or Obesity" Status: Completed Phase: Phase 2a Enrollment: 706 participants Study Period: 2018-2020 Location: Multi-country (US, Europe) Design: Randomized, double-blind, placebo-controlled Duration: 26 weeks Intervention: Cagrilintide 0.6/1.2/2.4/4.5 mg weekly Population: BMI 30 or 27 with comorbidity, no diabetes Key Results (26 Weeks): Mean Weight Loss: 10.8% at 4.5 mg (highest dose) 8.6% at 2.4 mg 6.0% at 1.2 mg 4.3% at 0.6 mg 3.0% with placebo 10% Weight Loss: 51% (4.5 mg) vs
W., McGlasson, B
If you'd rather not take a weekly injection, you can switch to the Wegovy pill
For the first 3 days (loading phase): Mix 1 scoop with 8 oz
With our state-of-the-art GMP-certified production facilities spanning 100,000 square meters and expertise in advanced reaction and purification techniques, we cater to diverse industries including pharmaceuticals, polymers, paints, water treatment, and more
In this article, well explain exactly what happens inside your body when you can take DayQuil and drink alcohol, how long you need to wait after taking DayQuil before drinking, the warning signs of liver damage you should never ignore, and why NyQuil is even more dangerous with alcohol
